A Practical Guide to GxP-Ready AI
For decades, pharma has validated software on one assumption, the same input gives the same output. Generative AI breaks that. Ask it the same question twice and the wording, or even the conclusion, can change. That’s harmless when you’re summarizing a meeting. It’s a problem when the answer feeds a batch record, a deviation investigation or a pharmacovigilance case.
AI governance in life sciences is how you handle that. It means showing that a system is fit for its purpose, that its outputs can be traced and reviewed, and that a named person is accountable for the decisions it influences.
Why AI Governance Requires a Different Approach in Pharma
The benefits are real: faster deviation reviews, less manual work on safety reports, quicker regulatory drafting. But each of these touches GxP data, patient data, or both. A marketing chatbot can get an answer wrong, and nobody is harmed. A model that helps classify a deviation can’t.
Three problems come up again.
Outputs vary. Computer system validation checks that a system meets defined requirements. With generative AI, results can shift with the prompt, the context, the data and the model version. A few good test runs don’t prove it will hold up in production. Teams need clear acceptance criteria, realistic test scenarios, documented limitations and monitoring after go-live.
ALCOA+ still applies. GxP records must be attributable, legible, contemporaneous, original and accurate, and complete, consistent, enduring and available. If AI contributes to a record, you need evidence of that contribution: the source data, model version, inputs and outputs, and who reviewed and approved the result. Picture an inspector asking why a deviation was closed the way it was. The AI’s summary alone won’t answer that.
Data is scattered. Many manufacturers run separate systems for finance, production and quality, with spreadsheets filling the gaps. If you can’t say which source is authoritative or what changed along the way, you can’t defend what a model built on that data tells you.
Treat Integration as Part of Governance
A common plan is to clean the data, deploy the AI, then sort out governance. In a live plant that rarely works. Master data changes, systems get upgraded and integrations evolve, so a model that behaves one way today may behave differently after a migration.
That’s why integration architecture matters. A governed integration layer records where data came from, how it moved and what was changed on the way. Platforms such as SAP Integration Suite can support this when configured properly, while point-to-point scripts and manual exports usually can’t. Even so, no platform makes you compliant by itself. Audit trails, access controls and retention still have to be set up for the process you’re running.
Before approving any pilot, ask four questions:
- Which system is the authoritative source for the data?
- Can the data be traced from that source to the model?
- Could the team reconstruct how a specific AI-assisted decision was reached?
- Does the output advise a person, or can it change a GxP record or trigger an action?
The last one matters most. A recommendation reviewed by a qualified person carries a very different risk from an automatic update to a regulated record.
What Regulators Expect
Regulators are paying attention. The FDA and the European Medicines Agency have both published material on AI in the medicines lifecycle, and the EU AI Act adds obligations for some systems depending on how they’re used. The details differ, but the message is consistent: show that the system is credible for its intended use, with controls that match the risk.
That idea is context of use. The same model might summarize meeting notes in one setting and help draft a CAPA justification in another. The technology is identical, but the consequences of a wrong answer aren’t. So, start governance with the use case: what is the AI doing, what could go wrong, and what evidence shows it’s fit for that job?
A Governance Model That Works
You don’t need a long policy to begin. You need five basics:
- An inventory of every AI use case, with its purpose, owner, data sources and risk level. Include departmental tools and pilots.
- Controls matched to risk. Light review for low-risk uses, documented validation and human sign-off for anything near GxP.
- Shared safeguards such as access control, logging, data protection and model version tracking, set up once for the whole platform.
- Clear accountability. Quality, IT, data privacy and the business agree who does what, with a named owner per use case.
- Ongoing monitoring of performance, model updates and changes in source data.
Bring Quality Assurance in before the pilot, not at go-live. If you find out late that inputs weren’t recorded or model versions weren’t tracked, that evidence is hard to recreate.
Frequently Asked Questions
Does AI require GxP validation?
It depends on the intended use. If AI influences a regulated process, record or decision, assess what validation and assurance it needs.
Can we use public LLMs with GxP data?
Only after checking confidentiality, data retention, whether your data is used for training, residency and auditability, and putting the right technical and contractual safeguards in place.
Where should we start?
With an inventory of the AI tools and pilots already in use. You can’t assess your exposure until you know what’s running.
Conclusion
The hard part of AI in pharma isn’t getting a useful answer from a model. It’s explaining where that answer came from, judging whether it can be trusted, and showing the decision was properly controlled. That takes reliable source data, traceable integrations, risk-based validation and clear accountability from day one, and that’s what GxP-ready AI looks like.
Add a Comment